Edition:
India

Catabasis Pharmaceuticals Inc (CATB.OQ)

CATB.OQ on NASDAQ Stock Exchange Global Market

7.09USD
12:42am IST
Change (% chg)

$0.09 (+1.29%)
Prev Close
$7.00
Open
$7.10
Day's High
$7.22
Day's Low
$7.00
Volume
39,645
Avg. Vol
24,095
52-wk High
$9.76
52-wk Low
$4.07

Latest Key Developments (Source: Significant Developments)

Catabasis Pharmaceuticals Announces Phase 3 Trial Enrolled Expected Patient Population
Monday, 16 Dec 2019 

Dec 16 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS ANNOUNCES PHASE 3 POLARISDMD TRIAL ENROLLED EXPECTED PATIENT POPULATION.CATABASIS PHARMACEUTICALS INC - TOP-LINE RESULTS FROM PHASE 3 POLARISDMD TRIAL ARE EXPECTED IN Q4 OF 2020.CATABASIS PHARMACEUTICALS INC - PHASE 3 POLARISDMD TRIAL IS ANTICIPATED TO SUPPORT AN NDA FILING IN 2021.  Full Article

Catabasis Pharmaceuticals Reports Third Quarter 2019 Financial Results
Thursday, 7 Nov 2019 

Nov 7 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS.Q3 LOSS PER SHARE $0.56.Q3 EARNINGS PER SHARE ESTIMATE $-0.64 -- REFINITIV IBES DATA.  Full Article

Catabasis - As Of Sept 30, Co Had Cash, Cash Equivalents, Short-Term Investments Of $40.6 Mln
Thursday, 7 Nov 2019 

Nov 7 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS INC - AS OF SEPTEMBER 30, 2019, CATABASIS HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $40.6 MILLION.  Full Article

Catabasis Pharmaceuticals Presents Findings From MoveDMD Trial Of Edasalonexent
Saturday, 5 Oct 2019 

Oct 5 (Reuters) - Catabasis Pharmaceuticals Inc ::COMPANY TODAY PRESENTED FINDINGS FROM MOVEDMD TRIAL OF EDASALONEXENT.IN PHASE 2 MOVEDMD TRIAL AND OPEN-LABEL EXTENSION, EDASALONEXENT WAS WELL TOLERATED.IN MOVEDMD TRIAL AND OPEN-LABEL EXTENSION FOR EDASALONEXENT, MAJORITY OF ADVERSE EVENTS WERE MILD IN NATURE.  Full Article

Catabasis Pharma Says Phase 3 PolarisDMD Trial Of Edasalonexent In Duchenne Muscular Dystrophy Has Exceeded Target Enrollment
Tuesday, 1 Oct 2019 

Sept 30 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS ANNOUNCES THE PHASE 3 POLARISDMD TRIAL OF EDASALONEXENT IN DUCHENNE MUSCULAR DYSTROPHY HAS EXCEEDED TARGET ENROLLMENT.CATABASIS PHARMACEUTICALS ANNOUNCES THE PHASE 3 POLARISDMD TRIAL OF EDASALONEXENT IN DUCHENNE MUSCULAR DYSTROPHY HAS EXCEEDED TARGET ENROLLMENT.CATABASIS PHARMACEUTICALS INC - TOP-LINE RESULTS EXPECTED Q4 OF 2020.CATABASIS PHARMACEUTICALS INC - TRIAL IS ANTICIPATED TO SUPPORT AN NDA FILING IN 2021.  Full Article

Catabasis Pharmaceuticals Inc Qtrly Loss Per Share $0.62
Tuesday, 14 May 2019 

May 14 (Reuters) - Catabasis Pharmaceuticals Inc ::QTRLY LOSS PER SHARE $0.62.CATABASIS PHARMACEUTICALS - AS OF MARCH 31, 2019, HAD AVAILABLE CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $51.7 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.70 -- REFINITIV IBES DATA.  Full Article

Catabasis Pharma Reports Q1 Loss Per Share Of $0.62
Tuesday, 14 May 2019 

May 14 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS.Q1 LOSS PER SHARE $0.62.Q1 EARNINGS PER SHARE ESTIMATE $-0.70 -- REFINITIV IBES DATA.AS OF MARCH 31, 2019, CATABASIS HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $51.7 MILLION.  Full Article

Catabasis Pharmaceuticals Announces Reverse Stock Split
Monday, 24 Dec 2018 

Dec 24 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT.CATABASIS PHARMACEUTICALS - WILL EFFECT A ONE-FOR-TEN REVERSE STOCK SPLIT OF ITS COMMON STOCK THAT WILL BE EFFECTIVE ON DECEMBER 28, 2018..  Full Article

Catabasis Pharmaceuticals Q3 Loss Per Share $0.08
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS.Q3 LOSS PER SHARE $0.08.Q3 EARNINGS PER SHARE VIEW $-0.13 -- THOMSON REUTERS I/B/E/S.AT QUARTER END, CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $43.2 MILLION, VERSUS $49.9 MILLION AS OF JUNE 30, 2018.  Full Article

Catabasis Pharmaceuticals Inc - Collaboration with university of Texas Southwestern
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Catabasis Pharmaceuticals Inc ::CATABASIS PHARMACEUTICALS INC - COLLABORATION WITH UNIVERSITY OF TEXAS SOUTHWESTERN.CATABASIS PHARMACEUTICALS -COLLABORATION TO EXPLORE POTENTIAL BENEFITS OF EDASALONEXENT ON CARDIAC FUNCTION IN DUCHENNE , BECKER MUSCULAR DYSTROPHIES.CATABASIS PHARMACEUTICALS INC - RESULTS ARE EXPECTED IN SECOND HALF OF 2019.  Full Article